Asset Publisher

The META Trial

Preventing and delaying the development of diabetes in Africa: A randomised placebo-controlled double-blind Phase III trial of metformin in HIV-infected persons with pre-diabetes

Duration
17/01/2025 - 31/12/2026
Coordinator
ISGlobal and University College London (UCL)
Funded by
European Union

The META Trial is the largest trial of metformin conducted in Africa. It is aimed at identifying a low-cost intervention to prevent or delay onset of diabetes in individuals living with HIV and pre-diabetes, who are on antiretroviral therapy (ART) in the continent.

Not only will it produce globally relevant evidence on this question, but in ancillary studies, we will compare diagnostic methods for diabetes and use various clinical data to describe diabetes and HIV-related complications in this population. Developing clinical skills and capacity for conduct of clinical trials is central to the capacity development aims of the META Trial.
 

Total Funding

1.800.000€

Our Team

Equipo ISGlobal

Other projects

INCENTIVE

Indo-European Consortium for Next Generation Influenza Vaccine Innovation

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art